| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Funestrand, Henrik, et al.
(författare)
-
Substandard and falsified medical products are a global public health threat. A pilot survey of awareness among physicians in Sweden
- 2019
-
Ingår i: Journal of Public Health. - : Oxford University Press (OUP). - 1741-3850 .- 1741-3842. ; 41:1, s. 95-102
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundSubstandard and falsified medical products are a public health threat, primarily associated with low- and middle-income countries. Today, the phenomenon also exists in high-income countries. Increased Internet access has opened a global market. Self-diagnosis and self-prescription have boosted the market for unregulated websites with access to falsified medicines.AimTo describe the state of knowledge and experience on SF medical products among emergency physicians (EPs) and general practitioners (GPs) in Sweden.MethodsAn online survey with anonymous answers from 100 EPs and 100 GPs. Physicians were recruited from TNS SIFO’s medical database. The term in the survey was ‘illegal and falsified medicines’ which was common in Sweden at that time. It corresponds well with the term ‘substandard and falsified medical products’ that the WHO launched shortly after our data collection. We report our results with this term.ResultsIn Sweden, 78.5% of the physicians had heard the term ‘illegal and falsified medicines’ and 36.5% had met patients they suspected had taken it. Physicians lacked awareness of the use of the reporting system and wanted more knowledge about how to deal with patients who have possibly used falsified medicines.ConclusionsTo meet the public health threat of SF medical products, physicians need more knowledge.
|
|
| 6. |
- Jayasekara, Harindra, et al.
(författare)
-
Alcohol consumption for different periods in life, intake pattern over time and all-cause mortality
- 2015
-
Ingår i: Journal of Public Health. - : Oxford University Press (OUP). - 1741-3842 .- 1741-3850. ; 37:4, s. 625-633
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Conventionally, cohort studies have assessed the association between alcohol and all-cause mortality by using alcohol intake at enrolment.Methods: In theMelbourne Collaborative Cohort Study, participants were asked about usual frequency and quantity of beverage-specific alcoholintake for 10-year periods starting at age 20 from which current, past and lifetime intakes were calculated.We used Cox regression to estimate hazardratios for mortality for 39 577 participants of theMelbourne Collaborative Cohort Study aged 40–69 at baseline.Results: After a mean follow-up of 15 years/person, we identified 4639 deaths. Associations between all-cause mortality and lifetime, current(baseline) and past intakewere J shaped, with lower mortality at low intake (e.g. ,40 g/day for men and 10 g/day for women using lifetime intake)and elevated mortality at higher intake. Formen, consistent light-to-moderate drinking (.0–39/.0–39 g/day) from age 20 to baseline agewasassociated with a 16% lower mortality, while heavy drinking at both ages (80/40 and 40/0 g/day) was associated with higher mortality comparedwith stable abstinence.Conclusions: Our findings support a reduced mortality risk associated with low-dose drinking but also highlight a higher mortality risk for consistentheavy drinking from a young age.
|
|
| 7. |
- Lundin, Susanne, et al.
(författare)
-
“Where and how do you buy medicines?” A pilot survey of consumption strategies among the public in Sweden
- 2019
-
Ingår i: Journal of Public Health. - : Oxford University Press (OUP). - 1741-3850 .- 1741-3842.
-
Tidskriftsartikel (refereegranskat)abstract
- Substandard and falsified (SF) medical products are a major danger to public health. They affect every region of the world, and have been identified in all major therapeutic categories. Studies from medicine, pharmacology, law and public health dominate this research area with a focus on the supply side. However, the spread of SF medical products cannot be fully understood without information about the demand side or a sociocultural perspective on market formation. The aim of this short report is to present findings from a pilot study that examines the attitudes of the Swedish public regarding consumption of medicines. Methods: We conducted a pilot survey in 2016 “Where and how do you buy medicines?” using LimeSurvey, an open-source online survey software. In total 155 respondents completed the survey. Results: The majority of respondents turn to doctors within healthcare for prescription-only medicines (POM). Simultaneously, some respondents would consider buying POMs without prior contact with experts even if medicines may come from unsafe sources.Conclusions: There is a tendency that people move away from formal healthcare towards an unregulated market. In parallel, people's approach to doctors becomes more personalized and pragmatic than in former patriarchal relationships. Risk becomes a negotiable concept.Keywords: Substandard and falsified medical products, consumption strategies, conception of risk, Swedish public
|
|
| 8. |
- Vilhelmsson, Andreas, et al.
(författare)
-
Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics
- 2018
-
Ingår i: Journal of Public Health. - : Oxford University Press (OUP). - 1741-3842 .- 1741-3850. ; 40:3, s. 646-651
-
Tidskriftsartikel (refereegranskat)abstract
- Background Little is known about how pharmaceutical companies lobby authorities or experts regarding procurement or the use of vaccines and antivirals. This paper investigates how members of Denmark's pandemic planning committee experienced lobbying efforts by Roche, manufacturer of Tamiflu, the antiviral that was stockpiled before the 2009 A(H1N1) pandemic. Methods Analysis of interviews with six of seven members of the Danish core pandemic committee, supplemented with documentary analysis. We sought to identify (1) arguments and (2) tactics used in lobbying, and to characterize interviewees' views on the impact of (3) lobbying and (4) scientific evidence on the decision to stockpile Tamiflu. Results Roche lobbied directly (in its own name) and through a seemingly independent third party. Roche used two arguments: (1) the procurement agreement had to be signed quickly because the drug would be delivered on a first-come, first-served basis and (2) Denmark was especially vulnerable to an influenza crisis because it had smaller Tamiflu stocks than other countries. Most interviewees suspected that lobbying had an impact on Tamiflu procurement. Conclusions Our study highlights risks posed by pharmaceutical lobbying. Arguments and tactics deployed by Roche are likely to be repeated whenever many countries are negotiating drug procurements in a monopolistic market.
|
|
